T cell-associated a 4 b 7 but not a 4 b 1 integrin is required for the induction and perpetuation of chronic colitis Anti-adhesion therapies that target a 4 integrins (e.g., natalizumab) are thought to work by blocking T-cell recruitment to the intestinal tissues in patients with Crohn's disease (CD); however, little direct evidence is available to confirm this contention. We wished to evaluate the importance of Tcell-associated a 4 integrins in a chronic colitis model in mice and to determine the effect of natalizumab treatment on intestinal tissue T-cell accumulation in human CD. Adoptive transfer of Tcells lacking a4 (a 4 À / À ) but not b 1 integrin into immunodeficient mice produced significantly attenuated disease. This was correlated with reduced numbers of colon CD4 Tcells compared with the control mice; however, tissue distribution of T helper type 1 (Th1) and T helper type 17 (Th17) cells and regulatory T cells (Tregs) was not affected by the lack of a 4 . Furthermore, a4 À / À T cells demonstrated defective homing to the chronically inflamed small intestines and colons.
INTRODUCTION
Development of Crohn's disease (CD) is associated with the accumulation of immune cells in the gastrointestinal tract. Emerging experimental and clinical evidence suggests that leukocyte-associated a 4 integrins may play an important role in the recruitment of these cells to the intestinal tissues, thus contributing to induction and perpetuation of chronic intestinal inflammation. [1] [2] [3] [4] [5] [6] The a 4 integrins belong to a family of heterodimeric proteins that mediate adhesive and signaling interactions between circulating leukocytes and endothelial cells. The a 4 chain can combine with either b 1 or b 7 chains to form very late antigen-4 (a 4 b 1 ) or lymphocyte Peyer's patch adhesion molecule 1 (LPAM-1; a 4 b 7 ) heterodimers, respectively.
Investigations into the roles of T cell-associated a 4 integrins in chronic mouse models of intestinal inflammation have been difficult to perform because of the embryonic lethality of the a 4 -deficiency in mice. 7 To circumvent this, b 7 -deficient (b7 À / À ) mice were utilized to address the relevance of a 4 b 7 and a E b 7 in experimental colitis. However, it produced contrasting results, with some studies demonstrating that adoptive transfer of b7 À / À T cells into the immunodeficient recipients delayed the onset but not the severity of colitis, 8, 9 whereas others showed attenuated disease. 3 Other indirect methods have been used to assess the role of a 4 integrins in the pathogenesis of experimental inflammatory bowel disease (IBD). For example, Picarella et al. 10 found that treatment of colitic mice with antibodies to b 7 integrin and mucosal addressin cell adhesion molecule-1 (MadCAM-1) attenuated disease development. Rivera-Nieves et al. 6 demonstrated that antibody-mediated blockade of either a 4 b 1 or a 4 b 7 individually did not attenuate chronic ileitis in SAMP1/Yit mice, whereas immune neutralization of both (or their endothelial ligands) provided significant protection. On the other hand, at least one study found that long-term administration of anti-a 4 integrin monoclonal antibody exacerbated colonic inflammation in Gai2-deficient mice. 11 Moreover, studies in cotton-top tamarin monkeys that spontaneously develop IBD-like disease in captivity revealed that administration of anti-a 4 (see ref 4) or anti-a 4 b 7 monoclonal antibodies 12 led to significant attenuation of their disease, suggesting a critical role of a 4 in the development of IBD.
Targeting leukocyte recruitment from blood into intestine has been successfully developed into a therapy for moderate to severe CD. Natalizumab is a monoclonal antibody that targets the a 4 integrin, thus blocking a 4 b 1 and a 4 b 7 molecules. Several clinical trials demonstrated the effectiveness of natalizumab at increasing the rates of clinical remission and the response rates 2, 13 or its efficacy as induction and maintenance therapy in a subset of CD patients who initially responded to this treatment.
14 Another anti-adhesion therapy is vedolizumab, a humanized antibody to a 4 b 7 . Recently completed phase 3 clinical trials demonstrated that vedolizumab was effective at treating ulcerative colitis and CD patients. 15, 16 The protective results obtained using monoclonal antibodies directed against the a 4 integrin or a 4 b 7 has been used as evidence to implicate the importance of T cells in the induction or perpetuation of disease. However, T cells are a diverse and multifunctional population that may not be uniformly affected by a 4 blockade. In the blood, expression of integrins a 4 and b 7 is markedly lower on Foxp3 þ regulatory T cells (Tregs) than conventional CD4 þ T cells, 17 despite Tregs being present in abundance in the intestinal mucosa. 18 In addition, in vivo administration of monoclonal antibodies may affect other cells. For example, a 4 b 7 is found on B cells, natural killer cells, monocytes, and eosinophils, whereas a 4 b 1 is expressed by neutrophils. [19] [20] [21] Although a 4 b 1 is not important in mediating T-cell recruitment to the gastrointestinal tract under steadystate noninflammatory conditions, in active CD, upregulation of its ligand, vascular cell adhesion molecule-1 (VCAM-1), by endothelial cells of the intestine 22 may contribute to leukocyte recruitment into the inflamed gut via a 4 b 1 /VCAM-1. 23, 24 Therefore, the objectives of this study were to ascertain the relative importance of T cell-associated a 4 integrins, namely a 4 b 7 and a 4 b 1 , in the induction of chronic gut inflammation in mice and to evaluate the importance of a 4 integrins for mucosal T-cell accumulation in human CD. To accomplish the first objective, we generated conditional mutant mice that selectively lack the T cell-associated gene a4itg or b1itg and evaluated the ability of a4 À / À and b1 À / À T cells to induce chronic colitis using T-cell transfer model of colitis. We found that deletion of a 4 integrin but not b 1 integrin in T cells significantly attenuated development of colitis in mice and reduced accumulation of T cells in the colons. These findings in mice also correlated with the reduced accumulation of CD4 T cells in the intestinal biopsies of human CD patients treated with natalizumab. Taken together, our results demonstrated a critical role for T cell-associated a 4 integrins in the induction and the perpetuation of CD and suggested a multifaceted role of this molecule in T-cell biology.
RESULTS

Adoptive transfer of CD45RB
high T cells lacking surface expression of a 4 integrin produced attenuated colitis in the immunodeficient recipient mice
To define the role of a 4 integrins in the pathogenesis of chronic colitis, we generated a conditional knockout mouse using cre-loxP-mediated recombination technology using two complementary approaches. For the first approach, we injected polyinosinic:polycytidylic acid (poly I:C) into Mx.cre þ a4 Figure S1E ). Significantly fewer CD4 T cells were isolated from the colons of a4 Figure S1F) . To our surprise, analysis of surface integrin molecules on CD4 þ T cells in the reconstituted a4 neg -RAG-1 À / À mice revealed re-expression of a 4 integrin even despite our most stringent gating during the sort (Supplementary Figure S2) . These data suggested that a 4 integrins are important for the T cell-induced chronic colitis, although cell sorting approach was insufficient to obtain a pure population of a4 neg T cells.
Mice with T cell-specific deletion of a 4 show normal levels of T cells in their intestine and gut-associated lymphoid tissue (GALT)
In order to delete itga4 gene in T cells, we crossed a4 loxP/loxP mice with CD4-cre mice. In the a4 loxP/loxP CD4Cre þ (hereafter a4 À / À ) mice, a 4 was not detected on the surface of CD4 and CD8 T cells and in B40% of B cells (Figure 1a) . At the same time, expression of other major adhesion molecules CD29 (b 1 integrin), CD11a (lymphocyte function-associated antigen-1 (LFA-1), aL integrin), CD18 (b 2 integrin), and CD54 (intercellular adhesion molecule 1 (ICAM-1)) was comparable to littermate control a4 loxP/loxP CD4Cre-(a4 Figure S3) .
Deficiency in b 7 integrin leads to a severe impairment in GALT formation and reduced numbers of intestinal lymphocytes. 25 Thus, we were somewhat surprised to find that a4
mice showed comparable number and structure of Peyer's patches compared with control mice (Supplementary Figure  S4A online). Moreover, CD4 and CD8 T-cell distribution in the intestine and the GALT were similar between the two groups (Supplementary Figure S4B ,C online). To determine whether lack of a 4 may affect some intestinal T-cell subsets more than others without changing the overall number, we carried out differential analysis of intestinal and GALT
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T-cell receptor-ab and -gd T cells. We did not find any significant alterations in T-cell numbers between a4 À / À and a4 þ / þ mice (Supplementary Figure S5) . (Figure 1b,c) . Flow cytometry analysis revealed comparable accumulation of CD4 T cells in the spleens of a4
mice, whereas their numbers in mesenteric lymph nodes (MLNs) and colonic lamina propria (LP) were significantly reduced ( Figure 1d ). Blood level of interferon-g (IFN-g) was significantly reduced in the noncolitic a4 À / À -RAG-1 À / À mice, whereas levels of interleukin (IL)-12p70, IL-17, and tumor necrosis factor-a were comparable to those with severe disease (Figure 1e ). 
À / À and WT-RAG-1 À / À mice were combined as ''a4 þ / þ ''. Significant differences are indicated as*Po0.05 and ***Po0.001.
Expression of surface adhesion molecules on T cells isolated from the recipients' intestinal tissues was comparable between the two groups (Figure 2a,b) . Interestingly, expression of a 4 b 7 integrin in the a4 þ / þ -RAG-1 À / À group was absent from the surface of T cells isolated from small intestine and colon LP, but was seen on T cells from MLNs (Figure 2a) , suggesting that it is downregulated following entry of T cells into the colon LP. Expression of a 4 or b 7 integrins paralleled tissue-distribution pattern that was seen with a 4 and a 4 b7 staining. Expression of b 7 integrin on some T cells in the a4 À / À -RAG-1 À / À group was because of pairing with CD103 (aE integrin). Noteworthy, colon LP T cells in both groups showed prominent expression of b 1 integrin (Figure 2a) . Lastly, T cells in both groups displayed high levels of expression of CD44 and lacked expression of CD62L (data not shown) confirming that they had acquired activated/effector phenotype. 
Lack of a 4 integrin does not affect in vitro polarization and tissue accumulation of Treg, Th1, or Th17 cells
Recent reports found that expression of a 4 integrins is important for recruitment of T helper type 1 (Th1) cells into the brain and central nervous system during the development of experimental autoimmune encephalomyelitis. 26, 27 Lack of a 4 integrin did not affect polarization of T cells into Th1, Th2, or Th17 subsets (Supplementary Figure S6A) .
In agreement with previous reports, 26, 27 we confirmed higher expression of a 4 integrin on the surface of Th1 cells as compared with Th17 cells (Supplementary Figure S6B) . Therefore, we next wished to determine whether transfer of a4 À / À T cells produced an imbalance between Th1 and Th17 cells in colitic mice. Despite significantly fewer T cells in the colon LP of the a4 À / À -RAG-1 À / À group, intracellular staining revealed a comparable percent of CD4 þ T cells producing IFN-g, IL-17, and both cytokines (Figure 3a,b) , indicating similar tissue levels of Th1 and Th17 cells. We also found comparable levels of foxp3
Taken together, our data suggest that lack of a 4 integrin does not affect in vitro polarization or in vivo distribution of Th1, Th17, or induced Tregs in colitic mice.
Homing of a4
À / À and a4 þ / þ T cells to the GALT and the intestinal mucosa Short-term homing experiments were performed next to compare the recruitment of a4 À / À and a4 þ / þ T cells into the secondary lymphoid tissues and the intestinal mucosa.
À / À T cells to the spleen, peripheral LN, and MLNs was largely unperturbed (Figure 4a, b) , whereas homing to the intestine was notably reduced (Figure 4a,c) . Phenotypic analysis of T cells recovered from these organs was consistent with the preferential homing of naive T cells for the secondary lymphoid tissues and activated/memory T cells to the extralymphoid tissues ( Figure 4d ). Taken together, these data suggest that lack of colitis in the a4
mice is not likely due to the defective priming of these cells in the MLNs but is due to a defect in effector T-cell homing to the gut.
Contribution of T cell-associated a 4 integrins during active colitis
Our experiments so far revealed a critical role of a 4 integrin in T-cell homing to the noninflamed gut. The effectiveness of natalizumab in some CD patients, however, suggests that a 4 may be also involved in homing to the inflamed intestines. Because a4 À / À -RAG-1 À / À mice do not develop colitis, we could not differentiate between contributions of T cellassociated a 4 during the initiation of colitis from its role in established disease. To circumvent this, we cotransferred CD45.1 wild-type (WT) and CD45.2 a4
high T cells into the same immunodeficient recipients. After disease developed, we compared the frequency of WT and mutant T cells in MLNs and colon LP of recipient mice. We found that the number of a4 À / À T cells was significantly reduced compared with WT T cells (Figure 5a,b) . This was not because of the reduced in vivo proliferation rates of a4 Figure S7) , thus suggesting that a4 À / À T cells are defective in their recruitment into the inflamed colon. We also performed intracellular staining and evaluated production of IFN-g and IL-17 by colon LP T cells. In agreement with data obtained from singly transferred a4
T cells as assessed by incorporation of bromodeoxyuridine (Supplementary
high T cells, we found comparable levels of IFN-g þ cells among WT and a4 À / À CD4 T cells in the cotransferred mice (Figure 5c,d) . However, we detected Prominent expression of LFA-1, ICAM-1, and b 1 integrins on colon LP T cells suggested that these molecules might be important for T cells during colitis development. Our previous data showed that T cells lacking LFA-1 but not ICAM-1 are unable to trigger chronic colitis. 28, 29 At the same time, the role of b 1 integrins in colitis has not been assessed. Moreover, upregulation of VCAM-1 on endothelial cells in active CD 22 suggests that circulating T cells can be recruited to the inflamed gut via a 4 b 1 /VCAM-1. To test the importance of
loxP/loxP xCD4-Cre neg (b1 þ / þ ) mice into immunodeficient recipients and observed development of colitis in these mice. Absence of surface expression of b 1 integrin on b1 À / À T cells was confirmed by flow cytometry (Supplementary Figure S8A ). Expression of other surface integrins was normal, including LPAM-1, that was in contrast to the initial findings with these mice. 30 Following adoptive transfer into immunodeficient recipients, b1 À / À T cells induced severe colitis with similar disease kinetics as did mice that received b1 þ / þ T cells (Figure 6a,b) .
We next examined the effect of b 1 integrin deletion on T-cell distribution in tissues. Absolute numbers of T cells in spleen, MLNs, colon LP, and bone marrow between mice that received b1 þ / þ and b1 À / À T cells were comparable (Figure 6c ). In addition, expression of a 4 and LPAM-1 integrins on their surface were also similar (Supplementary Figure S6D) . To determine whether lack of b 1 integrins might also affect Figure S8B) . Finally, expression of surface integrins on T cells isolated from different tissues from reconstituted mice were similar with the exception of b 1 integrin that was, as expected, absent from the surface of b1 Figure S9) in biopsy samples taken from CD patients before, during, and after therapy with natalizumab. As patients were not consistently sampled at all three time points, longitudinally paired analyses were not possible, but by unpaired analyses, treatment with natalizumab significantly reduced the absolute number of CD4 but not CD8 T cells per tissue section area (Figure 7a ). Tissue levels of Treg and Th1 CD4 T cells were not significantly affected, although a slight trend toward reduction was observed (Figure 7b ). The ratio of Tregs and Th1 cells to total CD4 or CD8 T cells, or to one another, was not significantly altered with treatment ( Figure 7c) . Thus, the immunosuppressive effect of integrin a 4 blockade on CD appears to result from a global reduction of CD4 T cells in the mucosa rather than a specific enrichment in the ratio of regulatory to pathogenic T cells. to work by blocking circulating T cells from entering the inflamed intestine. However, this idea has been largely supported by indirect evidence. Because a 4 b 7 is expressed on several cell types, including B cells, natural killer cells, monocytes, and eosinophils, it is not clear whether the beneficial effects of the different antibody preparations is directed against one or more of these leukocyte populations. Therefore, we addressed this question directly using adoptive transfer of T cells lacking surface expression of a 4 integrin. We found that adoptive transfer of a4 neg or a4 À / À T cells produced significantly attenuated colitis in RAG-1 À / À mice compared with those with intact a 4 integrin. In agreement with previous studies, 26, 27 our data show that lack of a 4 expression does not affect activation, proliferation, or polarization of naive T cells to a pathogenic Th1/Th17 phenotype in vitro or in vivo. Our short-term homing experiments revealed that migration of naive T cells to the MLNs was similar between a4 À / À and a4 þ / þ T cells. However, recruitment of activated/memory/ effector T cells lacking surface a 4 to the small intestine or colon LP was significantly compromised. These data are in agreement with the existing paradigm 34, 35 that under normal conditions, homing to the GALT involves redundant use of L-selectin and a 4 b 7 , whereas recruitment to small and large intestine is largely dependent on the latter molecule.
Which surface molecules are important for the homing of Th1 and Th17 cells is a subject of intense debate. As both subsets have been implicated in the pathogenesis of IBD, it is critical to delineate mechanisms how these cells traffic to the gut. Using b7 À / À mice, Wang et al. 35 demonstrated a critical role of a 4 b 7 for in vitro-polarized Th17 cell migration to the entire intestine. However, compared with Th1 cells, Th17 represent a relatively small population of LP T cells in colitic mice (Figure 3b ). In agreement with previous reports, 26, 27 we found that expression of a 4 integrin is substantially higher on the surface of Th1 cells compared with Th17 cells. Although loss of a 4 integrin led to fewer Th1 cells and more Th17 cells accumulating in the central nervous system during experimental autoimmune encephalomyelitis development, 26, 27 accumulation of Th1 cells or Th1/Th17 ratio in the gut was not perturbed even under the identical inflammatory environment that was created in mice cotransferred with WT and a4 À / À T cells. These findings in mice were corroborated by data obtained in human CD patients. Treatment with natalizumab led to a global reduction in intestinal CD4 T cells but did not affect Th1 or Tregs. Whether this correlates with sequestration of effector T cells in peripheral blood, as recently reported in natalizumab-treated multiple sclerosis patients, 36 or not remains to be established. Taken together, our data suggest that deficiency in a 4 broadly affects CD4 T-cell trafficking to the gut without preferentially affecting one Th subset more than the other.
Analysis of a 4 and a 4 b 7 integrin expression on the surface of T cells in colitic mice revealed dynamic tissue-specific changes between spleen, MLNs, and colonic LP (Figure 2a) . Whereas T cells isolated from MLNs expressed a 4 b 7 , it was not detected on those cells isolated from colon. Indeed, decreased expression of a 4 b 7 by intestinal T lymphocytes has been reported in IBD patients. 37 Thus, our data suggest that following migration into the intestine, T cells lose expression of gut-homing molecules a 4 b 7 and CCR9 (data not shown). It is not clear at the present time if this occurs only under inflammatory conditions or may also occur following migration of T cells into noninflamed intestine.
In contrast to the lack of a 4 b 7 , b 1 integrin was highly expressed on the surface of colon LP T cells in colitic mice. The b 1 integrin subunit can form heterodimers with a 1 -a 6 and aV achains to form a family of very late antigen molecules that can bind to extracellular matrix proteins laminin, fibronectin, collagen, and others. 38 Although expression of b 1 integrin may be important for T cells to receive survival and/or additional costimulatory signals in colon or bone marrow to maintain their effector functions during colitis, adoptive transfer of T cell lacking this integrin did not protect mice from developing colitis. We also found that T-cell numbers in the colon, secondary lymphoid tissues, and bone marrow were comparable. Therefore, among the a 4 integrins, a 4 b 7 plays a critical and nonredundant role in colitis pathogenesis, whereas a 4 b 1 appears to be dispensable for the colitis-inducing abilities of T cells.
Taken together, our study demonstrated a critical role for T cell-associated a 4 integrins in experimental colitis and human IBD. We directly assessed the relative importance of T cellassociated a 4 b 7 and a 4 b 1 in the induction of chronic, T cellmediated colitis. In addition to the role of a 4 integrins in induction of colitis, we definitively showed importance of these molecules for T cell's ability to traffic to MLNs and colon during active disease. Furthermore, our data with natalizumab-treated CD patients corroborated our findings in mice, by showing, for the first time, that natalizumab treatment reduced accumulation of CD4 T cells in the inflamed intestines. Finally, our results revealed an interesting dynamic of gut-homing molecule expression between circulating and tissue-associated T cells. Better understanding of the mechanisms that regulate surface integrin expression in effector T cells during their intravascular trafficking and beyond might provide additional clues to designing novel anti-adhesion therapies for IBD and related conditions. METHODS Animals. WT mice and RAG-1 À / À mice (B6.129S7-Rag1tm1Mom/J) on the C57Bl/6 background were purchased from The Jackson Laboratory (Bar Harbor, ME). a4 loxP/loxP Mice on a C57Bl/6 background were kindly provided by Dr Thalia Pappayanapoulou (University of Washington, Seattle, WA). 39 The b1 loxP/loxP xCD4-Cre þ (b1 À / À ) mice were kindly provided by Dr Yoji Shimizu (University of Minnesota, Minneapolis, MN). Mx.cre and CD4.Cre mice were purchased from the Taconic Farms (Madison, CT). To generate a 4 -deficient T cells, a4 loxP/loxP x Mx.cre þ mice were injected with 300-450 mg of polyI:C intraperitoneally in 1 Â phosphatebuffered saline every other day for a total of seven injections. At 2 weeks after the last injection, mice were bled from the tail vein to determine the efficiency of a 4 deletion from the surface of T cells using flow cytometry. Mice with o20% a 4 -negative cells of the total CD4 þ T cells were given additional 3-5 polyI:C injections. All mice that were used in subsequent experiments were used at least 2 weeks after the last polyI:C Antibodies. CD62L (L-selectin)-fluorescein isothiocyanate (FITC), CD44-phycoerythrin (PE), CD25-PE, CD3-PE-Cy5, and CD4-allophycocyanin were used for quantifying T-cell numbers in different tissues; CD11a-FITC, CD49d-PE, CD103-FITC, b7 integrin-peridinin chlorophyll protein-Cy5.5 (PerCP-Cy5.5), ICAM-1-PE, CD18-FITC, CD29-PE, and CD62L-FITC were used for analysis of surface expression of T-cell adhesion molecules. Antibodies were obtained from either BD Biosciences (San Diego, CA) or eBioscience (San Diego, CA).
Adoptive T-cell transfer model of colitis. For adoptive T-cell transfer experiments, spleens from several a4 loxP/loxP Mx.cre þ mice or polyI:Cinjected a4 loxP/loxP Mx.cre-mice were removed and pooled. Splenocytes were prepared for sorting as previously described. 41 Cells were stained with anti-CD4, -CD45RB, and -CD49d antibodies. For sorting CD4 þ CD45RB high cells (CD4 þ cells with 40% of the brightest expression of the CD45RB) were sorted into CD49d-negative (CD49d neg ) and CD49d þ populations using FACSAria (BectonDickinson, San Jose, CA) and were found to be 495% pure on postsort analysis. Age-and sex-matched RAG-1 À / À mice were injected intraperitoneally with 5 Â 10
þ CD45RB high CD49d neg T cells resuspended in 500 ml of phosphate-buffered saline. Control groups included RAG-1 À / À mice injected with 5 Â 10 5 of the CD4 þ CD45RB high obtained either from WT mice or from Mx.cre-mice treated with polyI:C at least 7 times (300-450 mg per mouse, intraperitoneally every other day).
For a4 loxP/loxP CD4-cre
loxP/loxP CD4-cre þ (b1 À / À ), and b1 loxP/loxP CD4-cre neg (b1 þ / þ ) adoptive transfers, spleens from several mice were pooled and purified by fluorescence-activated cell sorting into CD4 þ CD45RB high cells, and injected into age-and sex-matched RAG-1 À / À mice. Clinical evidence of disease (e.g., body weight loss and loose stool/diarrhea) was followed and recorded weekly from the time of the injection. At 8 weeks after transfer or when the animals lost 15-20% of their original body weights, mice were killed and their colons were excised and processed for histopathology and blinded scoring using previously published criteria. 41 For coinjection studies, WT (CD45.1) and a4
high T cells were coinjected (1:1 ratio, 0.5 Â 10 6 each cell type per mouse) into RAG-1 À / À mice.
Mononuclear cell isolation and analyses. Mononuclear cells were isolated from the spleen, MLNs, and colonic LP of reconstituted recipient mice and analyzed using flow cytometry as previously described. 28, 41, 42 For intracellular staining, mononuclear cells were activated overnight with antibodies to CD3 and CD28 with GolgiStop (BD Biosciences) added for the last 6 h before processing for surface staining, fixation, and permeabilization, followed by intracellular staining using antibodies and kits from eBioscience according to the manufacturer's protocol.
Cytokine measurement. Mononuclear cells were cultured in 96-well plate (100,000/well) in the presence of activating anti-CD3/CD28 antibodies for 24 h. Cytokine concentrations in culture supernatants were measured using 22-plex Mouse Cytokine/Chemokine Immunoassay (Millipore, Billerica, MA). For serum cytokine determinations, blood was collected from reconstituted mice, and serum was separated, aliquoted, and kept frozen until it was analyzed using mouse 32-plex (Millipore) according to the manufacturer's instructions. Samples were run on a Bio-Plex Luminex instrument (Bio-Rad Laboratories, Hercules, CA). Only those values that fell within the range of the standard curve were used in calculations unless otherwise specified. Data were analyzed using Miliplex Analyzer 3.1 xPONENT software (Millipore). For the cytokines that were out of range, cytokine-specific enzyme-linked immunosorbent assay was used (eBioscience) according to the manufacturers' protocol.
T-cell homing studies. For homing experiments, CD4 þ T cells from a4 À / À and a4 þ / þ control mice were isolated from spleens using EasySep CD4 þ negative selection kit (StemCell Technologies, Vancouver, BC, Canada) according to the manufacturer's protocol. Cells were labeled with carboxyfluorescein succinimidyl ester (Life Technologies) or CellTracker Blue CMAC (7-Amino-4-Chloromethylcoumarin) (Life Technologies, Carlsbad, CA) according to the manufacturer's protocol. Cells were washed, resuspended at 10 Â 10 7 / ml in phosphate-buffered saline, and 2 Â 10 7 cells (in 100-200 ml) were injected retro-orbitally into anesthetized RAG-1 À / À mice. At different times, mice were killed and the indicated tissues were harvested and processed as described above. For analysis, B1-2 Â 10 6 of FcRblocked cells were placed in individual wells of a 96-well plate and stained with fluorescently labeled antibodies to CD4. Mice were killed at indicated times and homing index of a4 þ / þ and a4 À / À cells in different tissues (HI TISSUE ) was calculated according to the method by Villablanca et al. 43 using the following formula:
Human studies. Through an institutional review board-approved protocol, electronic medical records were reviewed at a single hospital (Virginia Mason Medical Center, Seattle, WA) to identify 10 patients with CD (age 25-60, median 38, 50% female) who underwent colonoscopic biopsies before, during (e.g., within 1 month of last dose), or after (41.5 months since last dose) treatment with natalizumab. Five patients were also on infliximab, four were on a thiopurine, and eight were on a glucocorticoid during one or more biopsies. Paraffin blocks of surplus formalin-fixed tissue from these biopsies were then retrieved from the hospital's pathology archive, and sectioned in a de-identified manner. Limited clinical data on the patients biopsied were similarly retrieved and stored in a secure and de-identified manner. All work was performed in compliance with human subject research ethical standards and medical privacy laws.
Immunohistochemistry for human patients with CD. Tissue sections were stained by immunohistochemistry with antibodies to either FOXP3 (clone 236A/E7, eBioscience, San Diego, CA), CD4 (clone 4B12, Vector Labs, Burlingame, CA), or a combination of T-bet (clone 4B10, Santa Cruz Biotech, Santa Cruz, CA) and CD8 (clone 4B11, Novocastra, Devil, FL). Sections were photographed digitally in their entirety with the TissueFAXS platform (Tissue Gnostics, Tarzana, CA). Because CD4 þ and CD8 þ cells were often too confluent to reliably identify individual positive cells, the number of pixels staining positive for CD4 (Figure 7a, left panel) or CD8 (Figure 7a, right panel) were divided by the number of pixels staining positive for hematoxylin in their respective section. To quantify the CD4 þ T-cell subsets per tissue section area, the number of individual Foxp3 þ Tregs (Figure 7b , left panel) and T-bet þ Th1 cells (Figure 7b , right panel) were divided by the number of thousands of pixels staining positive for hematoxylin in their respective section, and comparisons between cohorts were made as in Figure 7a .
Staining for CD4 was not strong enough for two-color immunohistochemistry, but all detectable T-bet was detected in CD3 þ T cells (data not shown), virtually all of which in the LP are known to be either CD8 þ or CD4 þ . Therefore, to quantify Th1 cells (which should be CD4 þ , T-bet þ ), T-bet þ /CD8 À cells were manually counted within digital images by a blinded observer (J.D.L.) Foxp3 þ cells in the LP (all of which are CD4
þ by flow cytometry, data not shown) were counted digitally with ImageJ software (NIH, Bethesda, MD), using a color deconvolution program to isolate positively stained pixels. Because of confluency in certain areas, CD4 þ and CD8 þ cells could not be manually counted, and hence to measure the relative density of these cells in tissue section images, the number of pixels staining positive for either marker was quantified with ImageJ, and normalized against cells staining with hematoxylin (a nonspecific nuclear stain) to control for variations in total cellularity in each section.
Statistics. Statistical analyses were done using GraphPad Prism software (version 5, La Jolla, CA). Unless otherwise indicated, data are presented as mean ± s.e.m. Statistical significance between any two groups was evaluated using unpaired two-sided t-tests. Statistical significance between more than two groups was evaluated using a oneway analysis of variance. Statistical significance between selected groups was evaluated using Dunnett's multiple comparison test. A probability (P-value) of o0.05 was considered significant. 
